Replies to post #135 on Immune Pharmaceuticals Inc (fka IMNPQ)

[discoduc555]

This looks to good to be true. The recent private placement makes me think that they do not want to dilute this to hell and back (otherwise, why not go for more than $1 million?) While there are still warrants out at $1.65--it would be bad news if these ever got exercised--if I read right another batch recently expired, so it may be time to pump this up a bit. Would also be more favorable terms for a JV, no? Or a future secondary offering?

According to Scotty there are 11 large block owners holding 15% of the O/S but I don't know how recent that info is. If they can finance Phase III on AmiKet without destroying the stock then it's a slam dunk in my opinion.

How much could it cost to fund a 12-week Phase III trial for topical cream?

My bottom line: I think its worth a few thousand shares right now to see what happens and will buy hands over fist if the market cap ever drops below $10 million.

[surf1944]

EpiCept’s AmiKet™ Receives Fast Track Designation from FDA
Business WirePress Release: EpiCept Corporation – 7 hours ago

TARRYTOWN, N.Y.--(BUSINESS WIRE)--

Regulatory News:

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that AmiKet™ (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). AmiKet™ is the Company’s late-stage product for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with taxane-based chemotherapy.

The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and address unmet medical needs. According to the FDA, products with a Fast Track designation oftentimes receive priority review, which may reduce the standard review time by half. The Fast Track designation also allows for more frequent interactions with the FDA during the drug development process.

“We believe the FDA Fast Track designation is confirmation of the pressing need for therapies to treat neuropathic pain associated with CIPN,” said Jack Talley, President and Chief Executive Officer of EpiCept. “We expect the receipt of this designation will prove to be highly valuable in our current partnering efforts for AmiKet™.”

EpiCept previously announced the engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™. The engagement will focus on the identification and implementation of a strategy to optimize AmiKet's value for the Company's stockholders.

About AmiKet™

AmiKet™ is a prescription, topical analgesic cream containing amitriptyline 4% and ketamine 2% designed to provide relief from neuropathic pain, which affects more than 15 million people in the U.S. alone. In the first half of 2011, EpiCept announced positive results from a National Cancer Institute-sponsored study evaluating the efficacy and safety of AmiKet™ in chemotherapy-induced peripheral neuropathy (CIPN), a painful condition that frequently occurs following systemic chemotherapy and that may interrupt, delay or even prevent completion of potentially curative chemotherapy regimens. A safe and effective therapeutic option for neuropathic pain associated with CIPN would address a significant unmet medical need.